2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

Herrstedt, J.; Clark-Snow, R.; Ruhlmann, C.H.; Molassiotis, A.; Olver, I.; Rapoport, Bernardo Leon; Aapro, M.; Dennis, K.; Hesketh, P.J.; Navari, R.M.; Schwartzberg, L.; Affronti, M.L.; Garcia-Del-Barrio, M.A.; Chan, A.; Celio, L.; Chow, R.; Fleury, M.; Gralla, R.J.; Giusti, R.; Jahn, F.; Iihara, H.; Maranzano, E.; Radhakrishnan, Venkatraman; Saito, Mitsue; Sayegh, Paula; Bosnjak, S.; Zhang, L.; Lee, J.; Ostwal, V.; Smit, T.; Zilic, A.; Jordan, Karin; Scotté, F.

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

Herrstedt, J.; Clark-Snow, R.; Ruhlmann, C.H.; Molassiotis, A.; Olver, I.; Rapoport, Bernardo Leon; Aapro, M.; Dennis, K.; Hesketh, P.J.; Navari, R.M.; Schwartzberg, L.; Affronti, M.L.; Garcia-Del-Barrio, M.A.; Chan, A.; Celio, L.; Chow, R.; Fleury, M.; Gralla, R.J.; Giusti, R.; Jahn, F.; Iihara, H.; Maranzano, E.; Radhakrishnan, Venkatraman; Saito, Mitsue; Sayegh, Paula; Bosnjak, S.; Zhang, L.; Lee, J.; Ostwal, V.; Smit, T.; Zilic, A.; Jordan, Karin; Scotté, F.

URI: http://hdl.handle.net/2263/95143

Date: 2024-02

Abstract:

Nausea and vomiting are still considered to be two of the most troublesome adverse events (AEs) for patients treated with antineoplastic therapy. To optimise the utility of available antiemetic prophylaxis, updated reviews of the relevant literature and evidence-based guideline recommendations are crucial. The European Society for Medical Oncology (ESMO) and the Multinational Association of Supportive Care in Cancer (MASCC) completed the fourth Consensus Conference on Antiemetics for the prevention of nausea and vomiting in patients with cancer in Copenhagen in June 2015. This article is an update of the 2015 guidelines.

Show full item record